$54.650
+0.098 (+0.18%)收盤時
AKRO 資訊
AKRO 事件
Akero Therapeutics Reveals New Results from SYMMETRY and HARMONY Trials
Akero Therapeutics announced new findings from the SYMMETRY and HARMONY Phase 2b trials of efruxifermin in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis and pre-cirrhotic MASH, respectively. The data will be shared during two oral and two poster presentations at the 76th Annual American Association for the Study of Liver Diseases, AASLD, The Liver Meeting 2025, taking place November 7-11, 2025. New post-hoc analyses of 96-week data from the SYMMETRY trial reinforce the antifibrotic activity of efruxifermin in F4c MASH: Efruxifermin was associated with statistically significant improvements in clinically significant portal hypertension risk, as assessed by Baveno criteria. CSPH, a serious complication of cirrhosis, increases risk of hepatic complications. Significantly more participants treated with efruxifermin vs. placebo met thresholds for clinically meaningful improvements in noninvasive measures of fibrosis that predict reduced risk of liver-related events. Evaluation of liver biopsies from SYMMETRY using AI-assisted digital pathology corroborated the fibrosis improvements previously demonstrated by conventional pathology and revealed that efruxifermin consistently reduced total fibrosis and septa area, key features of cirrhosis related to disease severity.
Akero Therapeutics Sees 16.6% Increase
Akero Therapeutics is up 16.6%, or $7.74 to $54.23.
Akero Therapeutics Sees 16.5% Increase
Akero Therapeutics is up 16.5%, or $7.66 to $54.15.
Novo Nordisk to Purchase Akero Therapeutics for Up to $5.2 Billion in Cash
Akero Therapeutics (AKRO) announced that it has entered into a definitive agreement to be acquired by Novo Nordisk A/S (NVO) for up to $5.2B in cash. Under the terms of the agreement, Akero shareholders will receive $54.00 per share in cash at closing and a non-transferable Contingent Value Right. Each CVR will entitle its holder to receive a cash payment of $6.00 per share upon full U.S. regulatory approval of efruxifermin for treatment of compensated cirrhosis due to MASH by June 30, 2031. The upfront cash portion of the consideration represents an equity value of approximately $4.7B, a 19% premium to Akero's 30-day Volume Weighted Average Price, and a 42% premium to Akero's closing price on May 19, 2025 prior to market speculation. Combined, the upfront and potential contingent value payment represent, if achieved, an equity value of approximately $5.2B a 32% premium to Akero's 30-day VWAP, and a 57% premium to Akero's closing price on May 19, 2025 prior to market speculation. The transaction has been unanimously approved by Akero's Board of Directors and is expected to close around year-end, subject to approval by Akero shareholders and upon satisfaction of customary closing conditions including approvals by regulatory authorities.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。